

## Conflict of Interest

The author has declared no conflict of Interest.

# Optimal mid-upper-arm-circumference (MUAC) based discharge criteria for community-based-management of Severe Acute Malnutrition (CM-SAM) in India: a randomized controlled non-inferiority trial



LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



Sakib Burza, Raman Mahajan, Tansy Edwards, Chandra N. Shandilya, Alan de Lima Pereira, Vivek Kashyap, **Elisa Marino**, Montse Escruela, Nuria Salse, Amit Harshana, Rajib Dasgupta



# BACKGROUND

- ❖ Of the **13.6 million** severely wasted children globally approximately **half** live in India
- ❖ No National Guidelines for Community Management of Acute Malnutrition (CMAM)
- ❖ In-patient treatment remains the primary treatment modality

# BACKGROUND

## WHO RECOMMENDATIONS FOR NON-OEDEMATOUS SEVERE ACUTE MALNUTRITION (SAM)

## MID-UPPER ARM CIRCUMFERENCE (MUAC)

ADMISSION CRITERIA	DISCHARGE CRITERIA
Weight-for Height z-score (WHZ) <b>&lt; -3 SD</b>	Weight-for Height z-score (WHZ) <b>≥ -2 SD</b>
And/or	And/or
Mid-Upper Arm Circumference (MUAC) <b>&lt; 115 mm</b>	Mid-Upper Arm Circumference (MUAC) <b>≥ 125 mm</b>




# RATIONALE

- ❖ Previous evidence from India suggest:
  - Severe Acute Malnutrition associated with lower morbidity and mortality
  - MUAC only programming targets those at highest risk of death
  - Alternative discharge criteria of MUAC  $\geq 120$  mm vs. MUAC  $\geq 125$ mm results in similar long-term outcomes

# STUDY OBJECTIVES

- ❖ To evaluate whether using a **MUAC cut-off of  $\geq 120$  mm** instead of **MUAC cut-off of  $\geq 125$  mm** in children **6 to 59 months** for exit, from therapeutic feeding programs, results in a non-inferior relapse or death rate at **3 months** post exit
- ❖ To summarize relapse rates by arm within enrolment MUAC strata of  $<110$ mm and 110-114mm.

# WHAT DOES NON-INFERIORITY MEAN?



Intervention effect = % outcome in  $\geq 120\text{mm}$  arm  
- % outcome in  $\geq 125\text{mm}$  arm

*Two examples*

Non-inferior: UB < 13%

Inferior: UB > 13%

No **difference** in  
Outcome between  
arms

Margin = upper  
bound of one-  
sided 95% CI =  
13%

# DEFINING THE MARGIN


Relapse if discharged with MUAC $\geq 125$ mm	Relapse if discharged with MUAC $\geq 120$ mm	Margin of non-inferiority
<ul style="list-style-type: none"> <li>▶ Malawi study: 1.9% (155 children) at 3 months</li> <li>▶ Bihar study: 2.8% (211 children) at 12-18 months</li> <li>▶ Bihar study: 11.5% (52) children at 3 months</li> <li>▶ MSF Guidelines: relapse rate <math>&lt; 5\%</math></li> </ul>	<ul style="list-style-type: none"> <li>▶ Bihar study: 9.1% (253 children) at 3 months. Average of 3 food security period with relapse range between 3 – 13%</li> </ul>	<ul style="list-style-type: none"> <li>▶ 13 % margin is maximum allowable upper bound of CI around the difference in relapse or death rates</li> <li>▶ Positive trade off: doubling coverage capacity, improved compliance.</li> </ul>
$\leq 5\%$	9-10%	13%

- ❖ Assuming 9% relapse or death in the  $\geq 120$ mm discharge arm and conservatively assuming 1% relapse or death in  $\geq 125$ mm discharge arm, 726 children would provide 90% power to determine non-inferiority within 13%
- ❖ No more than 13% inferior to the 125mm discharge arm determined to be sufficient in terms of resource saving

# STUDY DESIGN

## Randomized, controlled non-inferiority trial

## Prospective observational cohort



**FOLLOW-UP AT COMMUNITY LEVEL** Follow-up at 3 and 6 months post exit for RCT, and post-recruitment for observational cohort

- ❖ This study was approved by the MSF Ethics Review Board and by the Ethical Review Boards of the Rajendra Institute of Medical Sciences, Ranchi and Jawaharlal Nehru University, New Delhi, India, and London School of Hygiene & Tropical Medicine, UK. Clinical Trials Registry – India number, CTRI/2017/12/010743



# RESULTS

## PRIMARY OUTCOMES AT 3 MONTHS

	Discharge $\geq 125$ mm (control)	Discharge $\geq 120$ mm
Randomized	<b>316</b>	<b>317</b>
Discharged Cured	194	236
Analysed (ITT) N	176	216
Died within 3 months of discharge, n (%)	0 (0.0, 95% CI: 0.0, 2.1)	1 (0.5, 95% CI: 0.0, 2.6)
Relapse to SAM or death at 3m, n (%), two-sided 95% CI	14 ( <b>8.0</b> , 95% CI: 4.4, 13.0)	31 ( <b>14.4</b> , 95% CI: 10.0, 19.7)
Unadjusted difference in relapse (one-sided 95% CI UB)	<b>6.4% (11.6%)</b>	
Adjusted difference in relapse (one-sided 95% CI UB)	<b>4.6% (9.0%)</b>	

# RESULTS

## SECONDARY OUTCOMES AT 6 MONTHS

	Discharge $\geq 125$ mm (control)	Discharge $\geq 120$ mm
Analysed (ITT) N	174	218
Died within 6 months of discharge, n (%)	0 (0.0, 95% CI: 0.0, 2.1)	1 (0.5, 95% CI: 0.0, 2.5)
Relapse to SAM or death at 6m, n (%), two-sided 95% CI	19 ( <b>10.9</b> , 95% CI: 6.7, 16.5)	41 ( <b>18.8</b> , 95% CI: 13.8, 24.6)
Unadjusted difference in relapse (one-sided 95% CI UB)	<b>7.9% (13.7%)</b>	
Adjusted difference in relapse (one-sided 95% CI UB)	<b>7.1% (12.7%)</b>	

# RESULTS

## RELAPSE AT 3 AND 6 MONTHS STRATIFIED BY ENROLMENT MUAC

	Outcome at 3 months		Outcome at 6 months	
	Discharge ≥125mm	Discharge ≥120mm	Discharge ≥125mm	Discharge ≥120mm
<b>MUAC &lt;110mm at enrolment:</b>				
Analysed (ITT), N	46	61	42	63
Relapse or death at 3m, n (% 95% CI)	4 (8.7, 95% CI: 2.4, 20.8)	16 (26.2, 95% CI: 15.8, 39.1)	7 (16.7, 95% CI: 7.0, 31.4)	17 (27.0, 95% CI: 16.6, 39.7)
Unadjusted difference in relapse (one-sided 95% CI UB)	<b>17.5% (29.0%)</b>		<b>10.3% (23.5%)</b>	
<b>MUAC 110-114mm at enrolment:</b>				
Analysed (ITT), N	130	155	132	155
Relapse or death at 3m, n (% 95% CI)	10 (7.7, 95% CI: 3.8, 13.7)	15 (9.7, 95% CI: 5.5, 15.5)	12 (9.1, 95% CI: 4.8, 15.3)	24 (15.5, 95% CI: 10.2, 22.2)
Unadjusted difference in relapse (one-sided 95% CI UB)	<b>2.0% (7.5%)</b>		<b>6.4% (12.7%)</b>	

# CONCLUSION

- ❖ MUAC  $\geq 120$ mm as discharge criterion suitable in children admitted with MUAC 110-114mm, but lack of evidence in those with MUAC  $< 110$ mm.
- ❖ 75 % of children are admitted with MUAC 110-114 and early discharge may result in an increased coverage capacity which is especially important in a country such as India with a high burden and limited resources.

# LIMITATION

- ❖ Lower than expected sample size;
  - Trial still powered for primary analysis due to less conservative relapse rate than assumed in control arm
  - Trial not powered to stratify by food security periods

# ACKNOWLEDGEMENTS

- ▶ The children, their families and communities
- ▶ MSF coordination and field teams in India
- ▶ MoH and Anganwadi centers staff, Ashas and all government staff involved
- ▶ Rajendra Institute of Medical Sciences, Ranchi
- ▶ Jawaharlal Nehru University, New Delhi
- ▶ London School of Hygiene & Tropical Medicine, UK

THANK YOU